FDA Letter Of Support

We are issuing this Letter of Support to sRNAlytics, Inc., to encourage further identification and study of isomiRs (microRNA variants) as exploratory monitoring biomarkers in patients who have symptomatic Huntington's disease (HD) or in people who are at risk of developing symptomatic HD (have the Huntingtin gene mutation).

HD is a genetic, progressive fatal disorder that results in neurodegeneration before the symptoms appear in patients. Presently, there are no qualified biomarkers capable of detecting and monitoring HD prior to the onset of symptoms. Disease staging is evaluated through various clinical assessments…

Download Letter Of Support

Biomarkers for the early-detection and monitoring of Huntington’s Disease

David W. Salzman1*, Joli Bregu2, Nathan S. Ray1, and Richard H. Myers1,2
1sRNAlytics Inc. AstraZeneca BioHub Incubator, 35 Gatehouse Drive, Waltham MA, 02451
2Boston University Medical School, Department of Neurology, 72 East Concord Street, Boston, MA, 02118
*corresponding author: david.salzman@srnalytics.com

Huntington’s Disease (HD) is a genetic disease caused by a CAG trinucleotide repeat in Exon1 of the huntingtin gene. Neurodegeneration results in the loss of cognitive and motor functions, and is caused by aggregation of mutant huntingtin protein in striatal neurons. Volumetric changes in the striatum can be detected decades before the manifestation of clinical phenotypes, indicating that therapeutic intervention would need to occur long before symptomatic presentation. In clinical practice and research settings, the Unified Huntington’s Disease Rating Scale (UHDRS) is utilized to evaluate a patients overall physical and neurological health. UHDRS is also the most widely used outcome measure for establishing drug efficacy. However, …

View Publication

sRNAlytics: Pioneering Small RNA Biomarker Discovery

PharmaTechOutlook Top 10 Drug Discovery and Development Solution Providers 2018

We’re at an exciting point in history and just scratching the surface of our understanding of biological information embedded within sequencing data. By unlocking the power of small RNAs and combining them with data science, we are enabling the devolopment of new therapeutics that treat the underlying drivers of disease,” exclaims David Salzman, founder of sRNAlytics.

Small RNAs regulate health and disease within all living things. Their expression patterns are conserved across species and can classify tissue and cell type of origin. They are found
in every type of sample and are extremely stable and easy to extract, making them excellent bioanalytical targets. “The exponential increase in research and publications about small RNA reinforces our excitement, but also highlights significant gaps in today’s approach to harness their power,” Salzman adds…

Read Article

AstraZeneca's Incubutor at the Boston BioHub announces on-boarding of sRNAlytics

August 08, 2018
AstraZeneca Pharmaceuticals LP

AstraZeneca’s Incubator at the Boston BioHub is excited to announce the arrival of sRNAlytics, its second company to on-board as a life science incubator resident. As a resident, sRNAlytics will benefit from free access to state-of-the-art laboratory facilities and equipment as well as access to mentoring from AZ and other resident company scientists within the vibrant research hub.

sRNAlytics developed a computational platform that combines Next-Generation Sequencing with big data analytics and machine learning…

Read Article

sRNAlytics to Accelerate its Biomarker Discovery Platform and Services at IndieBio

December 08, 2017
By BioSpace.com Breaking News Staff

Boston, MA and San Francisco, CA: sRNAlytics, an early-stage biotech startup based in Boston who has developed a software platform technology to identify small RNA biomarkers, announced today it will participate in the IndieBio Accelerator Program in San Francisco, CA.

IndieBio is an intensive 4-month business and research accelerator geared towards developing startups with promising, high-impact, technologies. SOSV, the venture capital firm…

Read Article

Massachusetts Startup sRNAlytics Develops Potent Small RNA Biomarker Sequencing Data

August 25, 2017
By Alex Keown, BioSpace.com Breaking News Staff

NEEDHAM, Mass. – When it comes to pharmaceutical drug development, biomarkers play a key role as de-risking tools. Biomarkers can reduce the time it takes to develop drugs, as well as reduce the cost of drug discovery by increasing endpoint data. 

This means biomarkers can play a key role in increasing the amount of money a pharma company can earn over the life of a drug patent. David Salzman, founder and chief executive officer of biomarker startup sRNAlytics, said that can translate into millions of dollars for drug companies..

Read Article